ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
Avatar

Single-molecule Sequencing Reveals Patterns of Pre-existing Drug Resistance that Suggest Treatment Strategies in Philadelphia-positive Leukemias

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Justin Pritchard
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Justin Pritchard
0 views
December 3, 2018
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
Scientific Session 5: Mechanisms of Resistance and New Targets
15:26
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

A Genome-scale CRISPR Knock-out Screen in Chronic Myeloid Leukemia I…

Feat. M. Lewis
13:48
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Single-molecule Sequencing Reveals Patterns of Pre-existing Drug Res…

Feat. J. Pritchard
12:49
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Modulation of p53 with the MDM2 Antagonist Idasanutlin, in Combinati…

Feat. D. Vetrie